Myriad Genetics Q4 revenue up 4% to $160.8M; GAAP EPS $(0.10), adjusted $(0.02)

MYRIAD GENETICS INC

2021-FY EPS reported -$0.35 revenue$690,600,000

Revenue $160.8M (+4% YoY); full-year $690.6M (+24%). Ex-divested businesses, Q4 revenue up 19%.
GAAP diluted EPS $(0.10); adjusted EPS $(0.02); GAAP gross margin 71.5%, adjusted 71.8%.
Hereditary cancer revenue $74.8M (-5% YoY); pharmacogenomics $29.4M (+63%); prenatal $30.1M (+43%).
FY2022 guidance: revenue $670-700M, adjusted EPS $0.00-$0.20, adjusted gross margin 70-72%.
Ended Q4 with $398.8M cash, no debt; Omicron variant adversely impacted hereditary cancer volumes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.